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Abstract: Glioblastoma (GBM) is a very aggressive and lethal brain tumor with poor prognosis. Despite new treat-
ment strategies, patients’ median survival is still less than 1 year in most cases. Few studies have focused exclu-
sively on this disease in children and most of our understanding of the disease process and its clinical outcome 
has come from studies on malignant gliomas in childhood, combining children with the diagnosis of GBM with other 
pediatric patients harboring high grade malignant tumors other than GBM. In this study we investigated, using 
array-CGH platforms, children (median age of 9 years) affected by GBM (WHO-grade IV). We identified recurrent Copy 
Number Alterations demonstrating that different chromosome regions are involved, in various combinations. These 
observations suggest a condition of strong genomic instability. Since cancer is an acquired disease and inherited 
factors play a significant role, we compared for the first time the constitutional Copy Number Variations with the Copy 
Number Alterations found in tumor biopsy. We speculate that genes included in the recurrent 9p21.3 and 16p13.3 
deletions and 1q32.1-q44 duplication play a crucial role for tumorigenesis and/or progression. In particular we sug-
gest that the A2BP1 gene (16p13.3) is one possible culprit of the disease. Given the rarity of the disease, the poor 
quality and quantity of bioptic material and the scarcity of data in the literature, our findings may better elucidate 
the genomic background of these tumors. The recognition of candidate genes underlying this disease could then 
improve treatment strategies for this devastating tumor.
Keywords: Pediatric glioblastoma multiforme, central nervous tumor, copy number alterations (CNA), copy number 
variations (CNVs), array-CGH, minimum common regions, deletion, duplication, amplification, tumorigenesis
Introduction
Glioblastoma multiforme (GBM; WHO-grade IV), 
the most frequent primary malignant brain 
tumor in adults, accounts for approximately 
7-9% of all central nervous (CNS) tumors in 
childhood [1, 2]. It is highly invasive, poorly 
responsive to conventional treatments [3] and 
median survival for children via conventional-
dose chemotherapy and radiotherapy is cur-
rently around 11-24 months. At 5 years, the 
overall survival rate is 5-20% [4].
In recent years, cytogenetic and molecular 
investigations have dramatically improved our 
understanding of the biology of malignant glio-
mas, identifying relevant molecular features. 
Pediatric primary GBM (pGBM), indeed, differs 
from its adult counterpart both in mean cumu-
lative survival and genetic profiling [5-10].
Adult and pGBMs have distinct molecular path-
ways of tumorigenesis [8]. Primary adult forms 
present amplification of EGRF [10] and inactiva-
tion of PTEN genes [11] in about 35-50% of 
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cases, while secondary adult GBMs, evolving 
from low-grade lesions, often have mutations 
of TP53 and, infrequently, amplification of 
EGFR or alteration of PTEN genes [12].
pGBM often exhibits TP53 mutations and only 
rarely shows EGFR amplification/overexpres-
sion [13, 14] or PTEN mutations [15], suggest-
ing that most pGBMs may be more similar to 
adult secondary glioblastomas than to primary 
ones. The frequency of mutations in TP53 is 
less than 40%, significantly less than those of 
secondary GBM of young adults that is around 
65% [16].
Moreover, in 20 pGBMs with mutational inacti-
vation of the p53 tumor suppressor gene, loss 
of p16 protein expression and overexpression 
of the EGFR protein has been described [17]. At 
variance with GBM adult form, no IDH1 and 
IDH2 mutations were found [18].
Array comparative genomic hybridization 
(aCGH) is a technique enabling high-resolution, 
genome-wide screening of genomic copy num-
ber variations (CNVs). aCGH is considered an 
essential and routine clinical diagnostic tool in 
patients with global developmental delay, intel-
lectual disability, autism, multiple congenital 
anomalies and dysmorphism [19]. Moreover, 
several CNVs have already been associated 
with both complex and common disorders, 
including cancer. Unlike with inherited DNA vari-
ations, cancer is usually characterized by 
somatic copy number alterations (CNA) allow-
ing identification of losses and/or gains crucial 
to the tumorigenesis process. This approach 
has also been applied in a wide variety of 
human brain tumors [20, 21].
Recent studies have shown significant differ-
ences in CNA between childhood and adult 
GBMs. Qu et al. demonstrated that in adult 
GBMs the most common events are duplica-
tions/amplifications, while in pGBMs heterozy-
gous deletions are more frequent. They demon-
strated the presence of two common regions of 
loss of heterozygosity (LOH) in 9p24.3-9p13.1 
and 17p13.3 both in pediatric and adult GBMs 
[22]. Moreover, in pGBMs, recurrent duplica-
tions of 1q, 3q, 2q and 17q as well as losses of 
chromosomal regions in 6q, 8q, 13q, and 17p 
have been described [23]. Paugh et al. also 
suggested that pediatric and adult GMBs were 
clearly distinguished by frequent gain of chro-
mosome 1q and lower frequency of chromo-
some 7 gain and 10q loss [24].
Based on these considerations, we used aCGH 
platforms to query 9 pGBMs, identifying recur-
rent CNA and establishing their minimum com-
mon regions of duplication and deletion. In 4 
cases we compared, for the first time, the tumor 
biopsy with blood samples of the same patient. 
We uncovered numerous target regions of inter-
est and hypothesized the possible role of some 
genes within them, whose function seems to be 
crucial for tumorigenesis and/or progression.
Materials and methods
Patients
The children included in this study, approved by 
the institutional Ethical Committee, are affect-
ed by GBM (WHO-grade IV). Informed consent 
was obtained from the parents or legal guard-
ians in all cases. We considered 9 patients, 5 
females and 4 males, with a median age of 9 
Table 1. Clinical characteristics of pediatric Glioblastoma Multiforme (pGBM)
ID Gender Age at diagnosis (years) Surgery  First-line Treatment Response FU (months) Status
P1 F 1 GTR HDCT-RT (60 Gy) CR 14 DOD
P2 M 9 PTR Vinorelbine+RT (60 Gy) PR 12 DOD
P3 M 4 PTR HDCT-RT (60 Gy) PR 3 DOD
P4 F 8 PTR Vinorelbine+RT (45 Gy) PR 19 DOD
P5 M 15 PTR Vinorelbine+RT (60 Gy) PR 8 DOD
P6 F 7 PTR TMZ+RT (60 Gy) PR 10 DOD
P7 F 10 GTR TMZ+RT (60 Gy) CR 14 AWD
P8 F 9 PTR TMZ+RT (60 Gy) PR 10 DOD
P9 M 13 By TMZ+RT (54 Gy) PR 12 DOD
GTR: gross total removal; PTR: partial total removal; By: biopsy; HDCT: high-dose chemotherapy; RT: radiotherapy; TMZ: temo-
zolomide; CR: complete response; PR: partial response; FU: follow-up; AWD: alive with disease; DOD: dead of disease.
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years (range, 1-15 years). Table 1 illustrates 
clinical characteristics. All received a first sur-
gery consisting of macroscopically complete 
excision of tumor in two cases (P1, P7), partial 
excision in 6 (P2-P6, P8) and a tumor biopsy 
only in one children (P9). All patients underwent 
radiotherapy, with dose and treatment tech-
niques being selected according to current 
front-line therapeutic studies of the Associa- 
zione Italiana Ematologia Oncologia Pediatrica 
(AIEOP) and literature data [25-27].
Seven children were treated with fractionated-
stereotactic radiotherapy at a dose of 60 Gy 
(P1-P3, P5-P8), one child (P4) affected by a spi-
nal tumor with 45 Gy on the tumor site, and P9, 
with brainstem GBM, received 54 Gy. Two 
patients (P1, P3) received high dose chemo-
therapy with autologous stem rescue, four 
patients (P6-P9) adjuvant temozolomide during 
and after radiotherapy and three patients (P2, 
P4, P5) adjuvant vinorelbine concomitant to 
and after radiotherapy. Median follow-up of the 
series was 12 months (range 3 to 19 months). 
At the end of the study, 8 patients (P1-P6, P8, 
P9) had died and one (P7) was alive with severe 
progressive disease.
Response criteria. Extent of disease was 
assessed by contrast-enhanced cranial MRI 
scan at the time of study entry and then after 
every two courses. In accordance with RECIST 
criteria, the following radiological categories 
were used for evaluation of response: (a) com-
plete response (CR) was defined as the disap-
pearance of all known disease for at least 4 
weeks; (b) partial response (PR) as at least 30% 
reduction in the longest diameter of measur-
able lesions for at least 4 weeks [28].
Histology
Surgical samples were routinely fixed in neutral 
buffered formol for 24 hours and embedded in 
paraffin for histopathological evaluation. 
Successively, one 5 µm thick histological sec-
tion obtained from each paraffin block with 
hematoxylin and eosin was stained. Histological 
diagnosis was carried out based on 2007 WHO 
classification criteria [29].
Microscopic examination showed dense cellu-
larity and composed glial cells with atypical fea-
tures and brisk mytotic activity. Prominent 
microvascular proliferation and necrosis were 
present in each case. Morphological features 
were consistent with the diagnosis of glio- 
blastoma.
Culture
Surgical fragments of brain tumors were col-
lected under sterile conditions, the tissue dis-
rupted mechanically with sterile blades and the 
fragments transferred into a 15-ml tube 
(SARSTEDT S.r.l., Italy) containing 5 ml of 
Dulbecco’s Modified Eagle Medium, incubated 
at 37°C for 5 minutes, centrifuged for 5 min-
utes at 1200 rpm and the pellet resuspended 
in DMEM/F-12 medium supplemented with 
10% fetal bovine serum (Euroclone, Italy) and 
1% penicillin-streptomycin antibiotics (Euro- 
clone, Italy). Cell suspension was aliquoted in 
60 mm Petri dishes and maintained at 37°C in 
a humidified atmosphere containing 5% CO2. 
After washing twice with phosphate buffered 
saline 1X (Euroclone, Italy), medium was 
replaced every 2-3 days during the 15 days of 
culture.
Array-CGH
We analyzed 9 pGBM specimens (P1-P9), 4 
peripheral blood samples (B3, B7-B9) and one 
primary culture (C8) of one pGBM. We also car-
ried out aCGH analysis of the parents of P7 and 
P9. Genomic tumor DNAs were extracted from 
GBM using QIAamp Mini Kit (QIAGEN®, Hilden, 
Germany) according to manufacturers’ instruc-
tions and quantified by NanoDROP 2000 
Spectrophotometer (Thermo Scientific, Walth- 
am, MA, USA). aCGH was performed using the 
Agilent Human Genome CGH Microarray Kit 
180K (Agilent Technologies, Santa Clara, 
California, USA). This platform is an oligonucle-
otide-based microarray with a resolution of 
about 40 kb.
Labeling and hybridization were performed fol-
lowing the protocols provided by Agilent. 500 
ng of purified DNA of the patient and of a con-
trol of the same sex (Coriell) were double 
digested with RsaI and AluI enzymes (Promega) 
for 2 h at 37°C, obtaining products between 
200 bp and 500 bp in length. Each digested 
sample was labeled for 2 h, minimizing light 
exposure, using the Agilent Genomic DNA 
Labeling Kit, using Cy5-dUTP for the patient 
DNA and Cy3-dUTP for the reference DNA. 
Labeled products were column purified (Amicon 
Ultra, Millipore) and prepared combining test 
and control sample according to the Agilent 
protocol. After probe denaturation and pre-
annealing with 50 μg of Human Cot-1 DNA 
(Invitrogen), hybridization was performed at 
65°C for 24 h in a rotating oven at 20 rpm. 
Images of the arrays were acquired with the 
Copy number analysis in pediatric GMB
296 Am J Cancer Res 2014;4(3):293-303
Table 2. Rearrangements identified by aCGH 180K
Tumors No CNA CNA
a) P1 8 6q21 (del), 6q21.1 (del), 9p24.2-9p24.1 (del), 9p21.3-9p21.2 (h-del), 9p21.2-9p13.2 (del), 10q23.3 (del), 15q26.3 
(del), 17p13.3 (del)
P2 27 1p36.12 (dup), 1p34.3 (dup), 1p31.1 (dup), 1p12 (dup), 1q21.1-1q4.1 (del), 3p14.3 (del), 4p (del-m), 4q (del), 5p (del), 
5q (del), 6q12-qter (del), 9p21.3-p13.2 (del), 10p (del-m), 10q11.22 (del), 10q23.1-qter (del), 13q12.11-q31.3 (del), 
13q31.3 (dup), 13q31.3-qter (del), 15q24.2 (del), 16p (del), 16q (del), 17p13.1-p12.1 (del), 17q12.1-17q12 (del), 18p 
(del), 18q (del), 19p13.3-19p13.2 (del), 21q (del)
P3 4 1q (dup), 4q35.2 (del), 7q31.33 (dup), 16p13.3 (del)
P4 8 5p14.3-pter (del-m), 6q25.1 (del), 13q (del-m), 15q13.3 (amp), 18p (del-m), 18q (del-m), Xp (del-m), Xq (del-m)
P5 23 1p (del-m), 1q (dup), 3p (dup-m), 3q (dup-m), 4q11.1 (amp), 4q13.1 (del), 6p (dup-m), 6q13-q14.1 (del-m), 6q14.1-qter 
(dup), 7q31.1-q32.2 (del-m), 8p (dup-m), 8q (dup-m), 10p (dup-m), 10q (dup-m), 14q (del-m), 15q (del-m), 17p13.2 
(del), 18p (dup-m), 18q (dup-m), 21q (dup-m), Xp (dup-m), Xq (dup-m)
P6 25 1p (dup), 1q (dup), 2p21 (del), 2p12 (dup), 2p11.2 (amp), 2q22.1 (del), 2q24.2 (dup), 2q34 (dup-m), 2q34 (del), 
3p21.2 (dup), 3q13.31 (dup), 3q13.31 (del-m), 7p (dup), 7q11.2-q22.2 (dup), 7q22.2-qter (amp), 9p (dup), 9q (dup), 
11p11.12-pter (dup), 11q (dup), 12q24.12 (dup), 19q13.12 (amp), 20p (dup), 20q (dup), Xp21.2-cent (dup), Xq (dup)
P7 25 1p36.22 (dup), 1q23.2-q23.3 (dup), 1q32.1 (amp), 2p25.3-p24.3 (dup), 2q22.1(del), 6p25.2-q26 (del-m), 7p22.2-
q36.2 (dup-m), 8p23.2-q24.23 (del-m), 9p24.2-q34.2 (del-m), 9p21.3 (h-del), 10p15.2-q26.2 (del-m), 11p15.4-q24.3 
(del-m), 12p11.22-p11.21 (amp), 13q (del-m), 14q (dup-m), 15q (del-m), 17p13.3 (dup), 17q11.2 (dup), 17q21.33 
(dup), 17q24.3 (dup), 17q25.3 (dup), 19p13.2 (del), 19p13.2 (dup-m), 21q (del-m), 22q13.2-q13.33 (del-m)
P8 65 1p (del-m), 1q25.21-qter (dup-m), 2pter-p23.2 (dup-m), 2p16.3-p12.1 (del-m), 2q21.2-q23.2 (del-m), 2q31.2-q32.3 
(dup-m), 2q32.3-q34 (del-m), 2q36.3-q37.2 (dup-m), 3q13.11-q13.31 (del-m), 4p (del-m), 4q13.3-qter (del-m), 5q 
(del), 7pter-p21.3 (del-m), 7p11.2 (amp), 7q11.21-q21.3 (del-m), 7q22.2-qter (dup-m), 8p23.2-p21.3 (del-m), 8p21.3-
p11.22 (dup-m), 8q11.22 (del-m), 8q11.23-q12 (dup-m), 8q12.1-q13.1 (del-m), 8q13.3-q21.2 (del-m), 8q21.2 (del), 
8q21.3-q23.1 (del-m), 8q23.2 (dup-m), 8q24.13-qter (del-m), 9p23-p22.2 (dup-m), 9p22.21 (del-m), 9p21.3-p23.31 
(h-del), 9p21.21-p21.12 (del-m), 9q21.11-q21.13 (dup-m), 9q21.12-q21.33 (del-m), 10p (del-m), 10q11.22-q21.31 
(del-m), 10q22.22-q22.21 (dup-m), 10q22.21-qter (del-m), 12p (del-m), 12q12-q13.12 (del), 12q13.13-q14.31 (dup-
m), 12q14.31-q21.1 (h-del), 12q21.12 (h-del), 12q21.31-qter (del), 13q12.11-q32.3 (h-del+del/-m), 14q (del), 15q 
(del), 16pter-p13.12 (del), 16p13.1-p11.2 (dup-m), 16p12.1-p12.11 (del-m), 17pter-p13.1 (del-m), 17q12-qter (del-m), 
18q21.2 (dup-m), 18q21.32-q22.3 (del-m), 19p13.3 (dup-m), 19p13.3-p13.11 (del-m), 19q (del-m), 20p (del-m), 20q 
(del-m), 21q21.1-qter (del-m), 22q (del-m), Xpter-p11.3 (dup-m), Xp11.3-p11.23 (del-m), Xq11-q21.1 (del-m), Xq21.1-
q21.33 (dup-m), Xq21.33-q22.1 (del-m), Xq22.1-q22.3 (dup-m), Xq22.3-q25 (del-m), Xq26.2-qter (dup-m)
P9 18 1p33-p21.1 (del-m), 1q21.1-q44 (dup), 2p25.1-p21 (amp), 2p16.3-p16.1 (dup), 4q26-q35.2 (del-m), 9p23 (del-m), 
10q21.2-q26.3 (del-m), 11q12.1 (dup), 14q11.2-q13.1 (del-m), 14q21.2-q21.3 (dup), 14q22.1 (del-m), 14q22.3-q24.2 
(del-m), 14q24.3-q31.3 (dup-m), 14q31.3-q32.32 (del-m), 17p13.3-p11.2 (del-m), 17p11.2 (dup), 18q11.1-q23 (del-
m), Yp11.32-q12 (del)
Colture No CNA CNA
b) C8 65 1p (del-m), 1q25.21-qter (dup-m), 2pter-p23.2 (dup-m), 2p16.3-p12.1 (del-m), 2q21.2-q23.2 (del-m), 2q31.2-q32.3 
(dup-m), 2q32.3-q34 (del-m), 2q36.3-q37.2 (dup-m), 3q13.11-q13.31 (del-m), 4p (del-m), 4q13.3-qter (del-m), 5q 
(del), 7pter-p21.3 (del-m), 7p11.2 (amp), 7q11.21-q21.3 (del-m), 7q22.2-qter (dup-m), 8p23.2-p21.3 (del-m), 8p21.3-
p11.22 (dup-m), 8q11.22 (del-m), 8q11.23-q12 (dup-m), 8q12.1-q13.1 (del-m), 8q13.3-q21.2 (del-m), 8q21.2 (del), 
8q21.3-q23.1 (del-m), 8q23.2 (dup-m), 8q24.13-qter (del-m), 9p23-p22.2 (dup-m), 9p22.21 (del-m), 9p21.3-p23.31 
(h-del), 9p21.21-p21.12 (del-m), 9q21.11-q21.13 (dup-m), 9 q21.12-q21.33 (del-m), 10p (del-m), 10q11.22-q21.31 
(del-m), 10q22.22-q22.21 (dup-m), 10q22.21-qter (del-m), 12p (del-m), 12q12-q13.12 (del), 12q13.13-q14.31 (dup-
m), 12q14.31-q21.1 (h-del), 12q21.12 (h-del), 12q21.31-qter (del), 13q12.11-q32.3 (h-del+del/-m), 14q (del), 15q 
(del), 16pter-p13.12 (del), 16p13.1-p11.2 (dup-m), 16p12.1-p12.11 (del-m), 17pter-p13.1 (del-m), 17q12-qter (del-m), 
18q21.2 (dup-m), 18q21.32-q22.3 (del-m), 19p13.3 (dup-m), 19p13.3-p13.11 (del-m), 19q (del-m), 20p (del-m), 20q 
(del-m), 21q21.1-qter (del-m), 22q (del-m), Xpter-p11.3 (dup-m), Xp11.3-p11.23 (del-m), Xq11-q21.1 (del-m), Xq21.1-
q21.33 (dup-m), Xq21.33-q22.1 (del-m), Xq22.1-q22.3 (dup-m), Xq22.3-q25 (del-m), Xq26.2-qter (dup-m)
Blood No CNVs CNVs
c) B3 3 4q35.2 (del), 7q31.33 (dup), 16p13.3 (del)
B7 3 15q23 (del) (paternal), 19p13.2 (del) (maternal), 21q22.11-q22.12 (dup) (maternal) 
B8 1 8q21.2 (del)
B9 2 11q12.1 (dup) (maternal), Yp11.32-q12 (dup-m) (de novo)
Rearrangements identified by aCGH using the Agilent Human Genome CGH Microarray Kit 180K. a: CNA in 9 pGBMs; b: CNA in primary colture of one pGBM; c: CNVs in 
four blood samples and their parental origin. P: tumor tissue; B: peripheral blood; C: primary tumor culture. “dup”: duplication (3 doses); “amp”: amplification (>4 doses); 
“del”: heterozygous deletion; “h-del”: homozygous deletion; -m: mosaicism.
Agilent C Scanner (Agilent Technologies, Santa 
Clara, CA, USA).
Each hybridization produced a pair of 16-bit 
images, which were processed using the Agilent 
Feature Extraction 10.5 software. Row data 
were analyzed using two different computation-
al approaches: (i) the Genomic Workbench 
Standard Edition 5.0 software by the ADM-2 
algorithm (breakpoint positions were reported 
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Figure 1. Circos plots of data obtained from the analysis of copy number alterations in pediatric glioblastoma by 
means of Genomic Workbench Standard Edition 5.0. Events present in the Database of Genomic Variants (DGV) 
were filtered out and are not reported. Tracks (from outer to inner) refer to samples P1, P2, P3, P4, P5, P6, P7, P8 
and P9 while the outer ring represent chromosomes with cytogenetic bands. A: Amplifications, mosaic duplication, 
duplications, deletions, mosaic deletions and homozygous deletion are reported as tiles (dark red, yellow, light red, 
light green, light blue and dark green respectively). Mosaicisms (plotted as thicker tiles) may overlap non-mosaic 
events. B: Peculiar gain events, mosaic duplications (yellow) and duplications (light red) observed in chromosomes 
1 and 7 for the aforementioned samples. C: Peculiar loss events (deletions, mosaic deletions and homozygous dele-
tions in light green, light blue and dark green respectively) observed in chromosomes 9, 13 and 18.
Copy number analysis in pediatric GMB
298 Am J Cancer Res 2014;4(3):293-303
according to Hg19, build 37) and (ii) a home-
made pipeline based on Shifting Level Model 
(SLM) and FastCall algoritms [30]. This method 
evaluates the probability classification of each 
segmented region into five biologically motivat-
ed statuses (double deletion, deletion, neutral, 
duplication or amplification), thus permitting us 
to discriminate double-copy from single-copy 
deletions and single-copy from multiple-copy 
duplications. In order to take into account sam-
ple heterogeneity, for each experiment, we set 
the cellularity parameter c equal to 0.7, assum-
ing 70% tumor purity.
Validation of CNVs and CNA by qPCR
Determination of CNVs and CNA by qPCR was 
performed using the Roche LightCycler® 480 
Detection System with DNA-binding dye SYBR 
Green I (Roche) according to the manufactur-
ers’ instructions. The primers were designed 
using Primer 3 software (http://biotools.
umassmed.edu/bioapps/primer3_www.cgi).
Statistical analysis
Statistical significance of events of deletion 




Table 2 shows the results of the aCGH analysis. 
We also summarized the cumulative chromo-
somal losses and gains (CNA) of pGBMs (a) and 
the constitutional CNVs present in blood sam-
ples of 4 pGBMs (B3, B7-B9) (c). In two of them 
the parental origin of constitutional CNVs was 
also established (B7, B9) (c). In the absence of 
control DNA from the same individual allowing 
us to discriminate whether the observed CNA 
are tumor-derived or constitutional CNVs, we 
did not consider those CNA designated as 
benign in the Database of Genomic Variants 
(DGV: http://projects.tcag.ca/variation/).
CNA were detected in all tumors (100%) and all 
chromosomes were involved at least once. The 
range of CNA was from 4 to 65 (mean 22.55) 
with a single patient showing 65 CNA both in 
tumor (P8) (a) and in primary culture (C8) (b).
The two different computational approaches, 
Genomic Workbench Standard Edition 5.0 soft-
ware and Shifting Level Model (SLM) and 
FastCall algorithms, showed overlapping re- 
sults as summarized in Figure 1.
The breakpoints of each CNA and CNVs are 
available upon request. The differences detect-
ed for the benign DGV not considered with the 
first computational approach are reported in 
Table 3.
CNA in loss
The most common deleted regions included: 
chromosome 4q13.1 (P2, P5), 6q14.1 (P2, P5, 
P7), 9p (P1, P2, P7-P9), 10q23.1-q26.3 (P2, 
P7-P9), 13q12.1-q34 (P2, P4, P7, P8), 15q (P5, 
P7, P8), 17p13.2 (P5, P8, P9), 18p11.32-q11.1 
(P2, P4) and 18q21.31-q22.3 (P2, P4, P8, P9) 
(Table 2).
In particular, P4 and P7 exhibited chromosome 
13 monosomy, P2 complex 13q rearrange-
ments (deletion 13q12.11-q31.3/duplication 
13q31.3/deletion 13q31.3-qter) and P8 a 
complex deleted region in homozygosity and 
heterozygosity (13q12.11-q32.3). Cases P5, 
P7, P8 showed chromosome 15 monosomy, P5 
and P7 with mosaic status.
CNA in gain
The most common gain regions involved chro-
mosome 1q32.1-qter (P3, P5-P9) and 7q31.32 
(P3, P6-P8). In particular, patients P5, P6 and 
P9 had duplication of entire chromosome 1 
long arm, while P7 had 1q23.2-q23.3 duplica-
tion and 1q32.1 amplification. Moreover, 
1q25.21-qter mosaic duplication was observed 
in P8 (Table 2). 
For all imbalances, gains and losses, the mini-
mal overlapping region is shown in Figure 1A. 
At the bottom we indicate the most frequent 
gains (Figure 1B interesting 1 and 7 chromo-
somes) and losses (Figure 1C referred to 9, 13 
and 18 chromosomes).
Real-time quantitative PCR validation
All CNVs and CNA were validated by Real Time-
PCR (data available on request).
Discussion
In the present study we have investigated 9 
pGBMs using aCGH and comparing constitu-
tional CNVs and tumor CNA in 4 of them. Given 
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the rarity of the disease, the poor quality and 
quantity of the bioptic material and lack of lit-
erature data regarding this comparison (CNVs 
and tumor CNA), our findings should better elu-
cidate the genomic background of these 
tumors.
We identified in our patients a variable number 
of CNA from a minimum of 4 to a maximum of 
65 per case (Table 2), involving different chro-
mosome regions, in various combinations, sug-
gesting genomic instability. The role of common 
CNVs, as those listed in the DGV (Table 3), has 
also been evaluated. Constitutional CNVs, in 
fact, may either represent benign polymorphic 
variants or be promoted to cancer. On the 
strength of these considerations, we decided 
to evaluate the benign DGVs recurring in at 
least 5 cases, in order to try to identify candi-
date genes that may be involved or in the 
genetic background for tumor progression or 
which could act together with a driver gene of 
cancer genesis. For example, the DGV on chro-
mosome 16, identified both as deletion (P2, 
P6, P7, P9) and a duplication (P3), contains tar-
gets of p53, the TP53TG3 and TP53TG3B 
genes.
Despite the fact that cancer is an acquired dis-
ease caused by various factors, there is clear 
evidence that inherited factors play a signifi-
cant role. Some of them represent loss-of-func-
tion mutations in tumor suppressor genes, 
resulting in a high, relative cancer risk among 
carriers. However, not only acquired but also 
inherited CNA may play a role in tumor predis-
position and possibly progression. For example, 
a CNV at chromosome 1q21.1, which included 
the neuroblastoma breakpoint family gene 
NBPF23, was found to be associated with the 
disease [32].
In our P3 case, the recurrent 16p13.3 deletion 
including A2BP1 gene was found in both tis-
sues (blood and tumor). A2BP1 is expressed 
exclusively in differentiated neurons and 
recently Hu J et al., using GBM as a model sys-
tem, identified A2BP1 deleted in 10% of GBM 
cases [33]. The role of this imbalance is known 
to be linked to intellectual disability, but our 
remark suggests that a congenital CNV could 
actually be a driver locus promoting cancer. In 
fact the patient with 16p deletion (B3, P3) was 
the only one who died 3 months after 
diagnosis.
In the two cases where we also analyzed the 
parents of our patients (P7, P9), all constitu-
tional CNVs were inherited from one parent 
except for a de novo Y chromosome rearran- 
gement.
In 5 patients we identified rearrangements on 
9p, variable in size: one region of homozygous 
Table 3. Benign DGV
Chr Start End P1 P2 P3 P4 P5 P6 P7 P8 P9 Genes
chr1 72768884 72795450 -2 2 0 0 -1 -2 2 0 -1 NEGR1
chr1 104115084 104211026 0 0 0 -2 -1 1 0 1 -1 AMY2B, AMY2A, AMY1A
chr1 149041962 149378236 0 -1 2 0 1 1 0 0 1 NBPF16
chr1 248727958 248785532 0 0 -2 0 1 1 0 1 1 OR2T34, OR2T10
chr1 248808422 249212638 0 0 1 0 1 1 0 1 1 OR2T27, OR14I1, SH3BP5L, 
ZNF672, ZNF692, PGBD2
chr2 89163891 89312560 1 0 1 0 0 1 2 0 2 RPIA 
chr4 69414770 69462408 0 -1 2 0 -2 1 0 0 -2 UGT2B17
chr8 39249381 39374759 0 -1 0 -2 -1 -2 2 0 0 ADAM32
chr11 55377939 55450758 2 2 -2 0 0 1 0 2 -1 OR4P4, OR4S2, OR4C6
chr12 9637352 9672628 -2 0 2 0 0 1 0 -2 -1 PZP 
chr14 106334936 106370856 2 0 2 0 0 0 2 2 2 TMEM121
chr15 20886611 21964061 0 -2 0 0 0 1 -1 -2 -2 NBEAP1, POTEB, NF1P2, CT60, 
chr16 32573837 33651735 0 -1 1 0 0 -1 -1 0 -1 TP53TG3, TP53TG3B
Benign DGV: the first column indicates the chromosomes containing recurrent benign DGV, the second and third columns the 
proximal and distal breakpoints of rearrangements, the fourth to twelfth columns indicate patients P1-P9 with the respective 
calls: -2 (homozygous deletion); -1 (heterozygous deletion); 1 (duplication); 2 (amplification). The thirteenth column shows the 
genes included in the benign DGV.
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deletion at 9p21.3 (P1, P7, P8) and another 
one with heterozygous 9p21.2-p21.1 (P1, P2, 
P7, P8) deletion.
Either homozygous or heterozygous 9p21.3 
deletion, including both or one of the two genes 
CDKN2A and CDKN2B, had been reported in a 
wide variety of tumors [34] including adult GBM 
[35]. These two genes act as a negative control-
ler of cell cycle progression [36]. Heterozygous 
deletion at 9p21.2-p21.1 includes 12 genes: 
TUSC1, C9orf82, LRRC19, TEK, C9orf11, 
LINC00032, MOB3B, IFNK, C9orf72, LINGO2, 
MIR876, and MIR873. We have modest infor-
mation about the cellular function of these 
genes. TUSC1 is interesting because it was 
found to be underexpressed in a study on lung 
cancer and it has been designated as a hypo-
thetical oncosuppressor gene [37].
We also identified recurrent large deletions of 
chromosomes: 13q, 18p, 18q and 15q. In 
regard to the 13q deletion, all of them included 
the RB1 gene (13q14.2), also implicated in 
pGBM genesis [38]. Four patients (P2, P7-P9) 
had LOH of 10q where the PTEN gene was also 
included. This gene has been identified as a 
tumor suppressor, mutated in a large number 
of cancers at high frequency [39, 40]. 
Interestingly, its deletion/mutation has also 
been described in astrocytic tumors [9, 41]. 
Three patients (P5, P8, P9) had heterozygous 
deletion at 17p13.2 in which 3 genes are pres-
ent: ZZEF1, CYB5D2 and ANKFY1 which have 
heretofore never been described in association 
with particular tumors. No rearrangements 
were found involving TP53 locus. 
The most frequent CNA in gain was 1q duplica-
tion (6 patients out of 9), 5 with a minimal over-
lapping region interesting 1q31.3-q44. This 
imbalance has been reported in several types 
of tumors [42, 43]. Gain of 1q is associated 
with poor prognoses in various pediatric tumors 
as well as anaplastic astrocytomas and glio-
blastoma [44], ependymoma [45] and medul-
loblastoma [46]. In our cases P3, P5, P6, P8 
and P9 the proximal breakpoint at 1q31.3 
maps a region of segmental duplications, pos-
sibly making it prone to genomic rearrange-
ments [47]. In P7 an amplification within the 
1q32.1 region was observed. The PLEKHA6 
gene encoding for a protein involved in intracel-
lular signaling that can act as one of cytoskele-
ton components was included in the ampli- 
fication.
We had four patients (P3, P6-P8) with duplica-
tion of chromosome 7 with a minimal overlap-
ping region at 7q31.32 containing 13 candidate 
oncogenes: GRM8, KIAA1549, ZC3HAV1L, 
UBN2, LUC7L2, KLRG2, HIPK2, PARP12, 
JHDM1D, RAB19, MKRN1, ADCK2, BRAF. BRAF 
plays a role in regulating the MAP kinase/ERKs 
signaling pathway. Acquired alterations in the 
BRAF gene have been associated with various 
cancers, including pilocytic astrocytoma (WHO-
grade I) [48, 49].
Conclusions and future perspectives
The past decade of research has been invalu-
able in increasing our understanding of GBM. 
However, several outstanding questions 
remain. First of all, tumor heterogeneity is still 
poorly characterized both in adult and pediatric 
GBMs. The cases reported up to now are spo-
radic at least as regards the published litera-
ture. This situation is compatible with a de novo 
mutation/variation--either germline or postzy-
gotic. In the latter case, we may assume both 
that the mutation occurs early in embryo and 
that it is limited to brain cells although the 
occurrence of the tumor in childhood may sug-
gest some DNA variation present in all body 
cells. Moreover, some genes located in recur-
rent benign DGV could act as genetic back-
ground which promotes cancer. Few whole-
genome studies profiling germline CNVs have 
been conducted in cohorts of cancer-predis-
posing patients negative for mutations in the 
major genes related to their specific cancer 
[50]. It is plausible that a germline variant asso-
ciated with tumor development is an event 
increasing the probability of tumor occurrence 
and decreasing the time necessary for cancer 
manifestation. For example, a 9p21.3 germline 
microdeletion was recently reported in two dif-
ferent types of tumors, colorectal [51] and 
breast cancer [52]. This finding indeed sup-
ports a pathogenic role of 9p21.3 germline 
deletion in cancer predisposition.
All our patients had a highly overlapping clinical 
history, a histological picture demonstrating a 
severe grade IV tumor since the onset of symp-
toms, and a poor prognosis with an average 
survival of 8 months (from 3 to 19). Thus, the 
condition seems to be genetically homoge-
neous, suggesting mutation(s) in a specific driv-
er gene acting by a dominant model, not exclud-
ing the occurrence of a second hit for initiating 
the tumorigenesis process.
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Our study was aimed to highlight any possible 
recurrent genomic imbalance associated with 
the origin and/or the progression of the tumor. 
We did not find any obvious CNA common to all 
patients although losses are more common 
than gains. Although six cases (P1, P2, P4, 
P7-P9) presented more CNA in loss than in 
gain, and 3 cases (P3, P5, P6) vice versa, the 
t-test showed no statistically significant differ-
ence between the events of deletion and 
duplication.
Literature data describe copy number imbal-
ances both in adult and pediatric GBMs and 
more deletions than duplications have been 
detected in pediatric cases than adult GBMs. 
Perhaps the most intriguing finding is the 
1q32.1-q44 duplication detected in 6 of our 
patients. Of them, P3 showed only this imbal-
ance in the tumor biopsy, a constitutional CNV 
(16p13.3 deletion) and died 3 months after 
diagnosis.
In summary, our data further define the CNA 
present in pGBM, showing that no specific 
imbalances are involved, apart from the 9p21.3 
and 16p13.3 deletions and 1q32.1-q44 dupli-
cation. The focal events we detected in form of 
amplification/deletion at the moment suggest 
that the A2BP1 gene is one possible culprit of 
the disease. Our data also could be used to 
compare the constitutional CNVs and CNA 
acquired, because at the moment there are no 
works in the literature that have developed our 
own experimental approach. Possibly only Next 
Generation Sequencing will be able to solve the 
problem.
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